# National Vaccine Advisory Committee, Subcommittee on Future Vaccines, Subcommittee on Immunization Coverage, and Subcommittee on Vaccine Safety and Communication: Meetings
In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee and subcommittee meetings.
*Name:* National Vaccine Advisory Committee (NVAC).
*Times and Dates:* 9 a.m.-2:15 p.m., June 3, 2003; 8:30 a.m.-3 p.m., June 4, 2003.
*Place:* Hubert H. Humphrey Building, Room 705A, 200 Independence Avenue, SW., Washington, DC 20201.
*Status:* Open to the public, limited only by the space available.
*Notice:* In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 a.m. and 8:30 a.m. or 12:30 p.m. and 1 p.m. Entrance to the meeting at other times during the day cannot be assured.
*Purpose:* This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.
*Matters to be Discussed:* Agenda items will include: a report from the National Vaccine Program Office (NVPO); an update on the Smallpox Vaccination Program; a report from the Acting Assistant Secretary for Health; an update on vaccine supply issues; a report from the polio vaccine stockpile workgroup; a report on the Institute of Medicine (IOM) Vaccine Safety Review Committee; a report from the IOM on their review of the Smallpox Vaccination Program; a report from the Influenza Immunization Summit; an update on pandemic influenza planning; a report from the Immunization Coverage Subcommittee, the Future Vaccines Subcommittee, and the Vaccine Safety and Communication Subcommittee; a discussion of compensation for vaccine administration; a discussion on Enhancing Public Participation in Immunization Decision-Making; a report from the Workgroup on Public Health Options for Implementing Immunization Recommendations; a report from the Polio Laboratory Containment Workgroup; a discussion of monitoring anthrax vaccine adverse events using the Department of Defense Medical Surveillance System; reports from the Advisory Commission on Childhood Vaccines/Division of Vaccine Injury Compensation, the Vaccine Related Biological Products Advisory Committee/Food and Drug Administration, and the Advisory Committee on Immunization Practices/National Immunization Program/National Center for Infectious Diseases.
*Name:* Subcommittee on Future Vaccines.
*Time and Date:* 2:30 p.m.-5 p.m., June 3, 2003.
*Place:* Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW., Washington, DC 20201.
*Status:* Open to the public, limited only by the space available.
*Purpose:* This subcommittee develops policy options and guides national activities that lead to accelerated development, licensure, and the best use of new vaccines in the simplest possible immunization schedules.
*Matters to be Discussed:* Agenda items will include an update on the proposed pneumococcal meeting; an update on the newborn vaccination meeting; CMV status report; and a presentation on Group A Steptococcus vaccines.
*Name:* Subcommittee on Immunization Coverage.
*Time and Date:* 2:30 p.m.-5 p.m., June 3, 2003.
*Place:* Hubert H. Humphrey Building, Room 705A, 200 Independence Avenue, SW., Washington, DC 20201.
*Status:* Open to the public, limited only by the space available.
*Purpose:* This subcommittee identifies and proposes solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.
*Matters to be Discussed:* Agenda items will include an update on publication of the newly revised Adult and Pediatric Immunization Standards; a discussion of adolescent immunization; Immunization Registries—Updates on the use of VFC funds for registry development standards of excellence; PCV7 update on impact of shortage on coverage and active bacterial core surveillance; a discussion of the draft report from the Workgroup on Public Health Options for Implementing Immunization Recommendations; updates on pneumococcal and influenza coverage; and a review of data on the burden of pneumococcal disease.
*Name:* Subcommittee on Vaccine Safety and Communication.
*Time and Date:* 2:30 p.m.-5 p.m., June 3, 2003.
*Place:* Hubert H. Humphrey Building, Room 425A, 200 Independence Avenue, SW., Washington, DC 20201.
*Status:* Open to the public, limited only by the space available.
*Purpose:* This subcommittee reviews issues relevant to vaccine safety and adverse reactions to vaccines.
*Matters to be Discussed:* Next Steps in Risk Communication: Reviews of IOM Immunization Safety Review Committee Recommendations, and of NVPO Workshop Recommendations; a discussion of the influenza communications programs; a discussion of next topics for the IOM Safety Review Committee; a review of the National Immunization Program Website; and, an update on thimerosal-related litigation.
Agenda items are subject to change as priorities dictate.
*Contact Person for More Information:* Gloria Sagar, Committee Management Specialist, NVPO, CDC, 4700 Buford Highway M/S K-77, Chamblee, Georgia 30341, telephone 770/488-2040.
The Director, Management Analysis and Services Office, has been delegated the authority to sign *Federal Register* notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: May 7, 2003.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.